

1 **Supplementary Information for**

2

3 **Akt phosphorylation of neuronal nitric oxide synthase regulates gastrointestinal**
4 **motility in mouse ileum**

5

6

7 **Damian D. Guerra, Rachael Bok, Vibhuti Vyas, David J. Orlicky, Ramón A. Lorca, and K.**
8 **Joseph Hurt**

9

10 **Corresponding author: K. Joseph Hurt**

11 **Email: K.Joseph.Hurt@ucdenver.edu**

12

13

14 **This PDF file includes:**

15

16 **Supplementary text**

17 **SI Appendix Figs. S1 to S13**

18 **SI Appendix Tables S1 to S2**

19 **References for SI reference citations**

20 **Supplementary Materials**

21 *Animals*

22 **Ethics statement:** The University of Colorado Institutional Animal Care and Use Committee approved
23 all animal experiments and procedures (IACUC protocol 90).

24

25 **Wildtype (WT):** WT mice were C57Bl/6 from Charles River laboratories (Wilmington, MA) or
26 genotyped WT siblings of nNOS^{S1412A} homozygotes.

27

28 **eNOS KO:** eNOS KO mice from the Jackson Laboratory (Bar Harbor, ME) stock 002684 are
29 homozygous for the *NOS3*^{tm1Unc} allele. The *NOS3*^{tm1Unc} allele replaces 129bp of exon 12, which encodes
30 the calmodulin (CaM) binding domain, with a premature stop codon (1).

31

32 **nNOS α KO:** nNOS α KO mice from the Jackson Laboratory stock 002986 are homozygous for the
33 *NOS1*^{tm1Plh} allele. Since the *NOS1*^{tm1Plh} allele lacks the first nNOS exon, the resulting protein lacks amino
34 acids 1-159 and no longer localizes to the plasma membrane (2, 3).

35

36 **nNOS^{S1412A}:** The nNOS^{S1412A} (S1412A) knock-in mouse contains a point mutation substituting nNOS
37 serine-1412 with non-phosphorylatable alanine. We developed nNOS^{S1412A} mice with assistance from the
38 CU Anschutz Transgenic and Gene Targeting Core.

39

40 We amplified a 6180 bp fragment containing *M. musculus* neuronal nitric oxide synthase (*nNOS/NOS1*)
41 exons 27-29, and intervening introns (81,988-88,168bp downstream of the nNOS start codon), from BAC
42 RP24-164C18 with primers containing 5` XhoI and ClaI sites and a 3` SpeI site. BAC RP24-164C18
43 contains bp 118,280,651-118,451,991 of *M. musculus* chromosome 5, which includes the entire *nNOS*

44 gene. We cloned the nNOS homology amplicon into a pBlueScript that lacked a NotI site by cutting both
45 the vector and the amplicon with XhoI and SpeI, yielding pBS_nNOS.

46

47 We generated the nNOS^{S1412A} mutation by overlapping PCR: for the 5` PCR product (84,979-85,629bp
48 downstream of the nNOS start codon), the forward primer contained an EcoRV site, and the reverse
49 primer's 5` end encoded the Ser → Ala mutation (TCC→GCG). For the 3` PCR product (85,630-
50 86,659bp downstream of nNOS start codon), the forward primer's 5` end contained the first nucleotide
51 after the mutation, and the reverse primer contained a NotI site. We cut the resulting nNOS^{S1412A} overlap
52 fragment and pBS_nNOS with EcoRV and NotI, and the nNOS^{S1412A} overlap fragment was cloned into
53 the cut vector to yield pBS_nNOS(A). For positive and negative selectable markers, we added neomycin
54 phosphotransferase flanked with loxP sites (LNL) and thymidine kinase (TK) to pBS_nNOS(A). The
55 LNL contained 5` and 3` AflIII sites and was cloned in the antisense orientation relative to the nNOS^{S1412A}
56 overlap fragment between exons 27 and 28. The TK negative selection marker was cloned in the sense
57 orientation downstream from the nNOS^{S1412A} overlap fragment.

58

59 We electroporated the ClaI-linearized targeting vector into mouse EC7.1 embryonic stem cells (mixed
60 C57Bl/6 x 129 background), electroporated Cre (New England Biolabs; Ipswich, MA) into G418-
61 resistant cells to excise LNL cassettes, and karyotyped clones as before (4). We injected karyotypically
62 normal clones into C57Bl/6 blastocysts, after which chimeric blastocysts were transferred into
63 pseudopregnant C57Bl/6 mice to produce F0 chimeras. We genotyped chimeric progeny by three
64 methods: 1. Primers specific to the excised neomycin resistance gene. 2. Primers specific to the remaining
65 loxP site and adjoining nNOS sequence after successful Cre recombination. 3. A single nucleotide
66 polymorphism Transnetyx (Cordova, TN) assay specific to the nNOS^{S1412A} mutation. nNOS^{S1412A}-positive
67 and Neo^R-negative chimeras were crossed to C57Bl/6 mice (Charles River laboratories). We identified
68 non-chimeric nNOS^{S1412A} heterozygotes by genotyping method 3 and backcrossed male heterozygotes to
69 C57Bl/6 females. We further purified genetic backgrounds by crossing nNOS^{S1412A} heterozygous females

70 to C57Bl/6 males to replace the EC7.1 cell-inherited Y chromosome. All nNOS^{S1412A} homozygotes
71 (Hom.), heterozygotes (Het.), and wildtype (WT) siblings used in this paper were F5-F7 generation of
72 repeated backcrosses of nNOS^{S1412A} to C57Bl/6.

73 Our nNOS^{S1412A} knock-in mutant is available upon request. Please address all inquiries to the
74 corresponding author.

75

76 **nNOS^{S1412A} eNOS KO:** We generated mice doubly homozygous for eNOS knockout and the nNOS^{S1412A}
77 mutation by mating nNOS^{S1412A} and eNOS KO mice.

78

79 *Reagents and antibodies*

80 Millipore Sigma (Burlington, MA) provided inhibitors of muscarinic (atropine, A0132) and α -
81 (phentolamine, P7547) and β - (propranolol, P0884) adrenergic signaling, inhibitors of cyclooxygenase
82 (indomethacin, I7378) and nNOS/iNOS/eNOS (L-NAME, N5751), the NK-1 agonist substance P (SP;
83 S6883), recombinant PKA (14-440), DTT (D0632), protease inhibitors (PI, P8340), phosphatase
84 inhibitors (PhosI, P5726), 2',5'-ADP sepharose 4B (GE17-0700-01), and all bulk reagents. ThermoFisher
85 (Waltham, MA) produced myristoylated PKA inhibitor peptide residues 14-22 (Myr-PKI, 77409) and all
86 LC-MS solvents. Cayman Chemical (Ann Arbor, MI) made the inhibitors of PKA (H-89, 10010556) and
87 nNOS/iNOS (1400W, 81520). The Akt inhibitors MK-2206 (MK, A3010) and Akti-1/2 (Akti, ab142088)
88 were from Apex Bio (Houston, TX) and Abcam (Cambridge, Cambridgeshire, UK), respectively. Santa
89 Cruz Biotech (Dallas, TX) produced the PKG inhibitor Rp-8-Br-cGMPs (sc-200323).

90

91 ImmunoStar (Hudson, WI) provided rabbit polyclonal anti-nNOS N-terminal peptide residues 134-148
92 (24431). Abcam produced rabbit polyclonal anti-nNOS peptide residues 1411-1425 phosphorylated at
93 S1412 (ab5583). Cell Signaling (Danvers, MA) generated rabbit monoclonal anti-PKG1 (3248S) and
94 rabbit polyclonal anti-PDE5 (2395S). Cayman Chemical provided rabbit polyclonal anti-sGC β (160897).

95 Novus Biologicals (Littleton, CO) produced chicken polyclonal anti-PGP9.5 (NB110-58872). Li-Cor
96 Biosciences (Lincoln, NE) provided goat anti-rabbit IRDye-680RD (925-68071) and goat anti-mouse
97 IRDye-800CW (925-32210). Abcam produced goat anti-chicken Alexa Fluor 488 (ab150169) and goat
98 anti-rabbit Alexa Fluor 594 (ab150080).

99

100 *Buffers*

101 **Krebs:** 118mM NaCl + 4.7mM KCl + 1.2mM MgSO₄•7H₂O + 25mM NaHCO₃ + 1.2mM KH₂PO₄ +
102 11mM glucose + 5mM HEPES + 50μM EDTA + 3.3mM CaCl₂.

103 **Ca²⁺-free Krebs:** CaCl₂ was omitted and 100μM EGTA was included.

104 **PBS:** 138mM NaCl + 2.7mM KCl + 10mM KH₂PO₄/K₂HPO₄, pH 7.4 at 25 °C.

105 **PBT-2,4:** PBS + 0.1, 0.2, or 0.4 % (v/v) Triton X-100.

106 **PBTW:** PBS + 0.1% (v/v) Tween-20.

107 **Protein extraction buffer:** 25mM Tris-HCl (pH 7.5 at 25 °C) + 1mM EGTA + 1mM DTT + 0.4% (v/v)
108 Triton X-100 + 1x PI + 1x PhosI.

109 **Affinity purification buffer:** 100mM Tris-HCl (pH 7.5 at 25 °C) + 150mM KCl + 2mM EGTA+ 2mM
110 EDTA+ 0.4% (v/v) Triton X-100 + 3.3% (v/v) glycerol + 1mM DTT + 50mM NaF + 5mM Na-
111 pyrophosphate + 30mM β-glycerophosphate + 1mM Na-orthovanadate + 2x PhosI + 2x PI.

112 **Affinity wash buffer:** 100mM Tris-HCl + 2mM EGTA+ 2mM EDTA + 1mM DTT + 17mM NaF +
113 1.7mM Na-pyrophosphate + 10mM β-glycerophosphate + 0.3mM Na-orthovanadate + 1x PhosI + 1x PI.

114

115 **Supplementary Methods**

116 *Tissue collection, protein extraction, and immunoblotting*

117 To assess how EFS affects nNOS phosphorylation, we flash-froze ileal rings with liquid nitrogen-chilled
118 forceps immediately following EFS. The lag time between the end of EFS and forceps-mediated tissue
119 vitrification was ≤5 sec. To assess how genotype affects protein expression in **Fig. 4C-D**, we flash-froze

120 ileal rings from freshly-euthanized animals after brief exposure to Ca²⁺-free Krebs during ileal lumen
121 perfusion. We extracted ileal protein with ice-cold protein extraction buffer in an equal volume of 0.9-
122 2.0mm diameter stainless steel beads (Next Advance; Troy, NY) subjected to 3 x 5 min pulverization
123 cycles in a Bullet Blender bead mill (Next Advance) at 80% power. We centrifuged homogenates for 10
124 min at 16,000 x g and retained the supernatant for immunoblotting. We determined protein concentration
125 by the Pierce 660nm protein assay (ThermoFisher). See **SI Appendix Fig. S10** for confirmation of NO
126 signaling pathway antibodies using positive (high expressing) and negative (low expressing) tissues.
127 Purification of phosphorylated ileal nNOS was conducted as before (5) with the following modifications:
128 We extracted protein with affinity purification buffer and incubated 16,000 x g supernatants of 4-8 ileal
129 ring lysates in batch with equilibrated 2', 5' ADP sepharose 4B at a 2:1 ratio of extract to beads for 3-4
130 hours at 4 °C. Beads were washed once with affinity purification buffer, once with affinity wash buffer,
131 and finally eluted at 95 °C with a 1:1 (v/v) mixture of affinity wash buffer and 6x Laemmli sample buffer.
132
133 To visualize protein from tissue lysates, we transferred SDS-PAGE resolved proteins to Immobilon-FL
134 PVDF membranes (ThermoFisher). We washed membranes 3 x 5 min with PBS and blocked for 60 min
135 with 10% (w/v) non-fat dry milk in Licor Odyssey buffer (phospho-nNOS blots) or 2.5% non-fat dry milk
136 in PBS (all other antigens). After blocking, membranes were incubated with primary antibodies overnight
137 at 4 °C at the following concentrations in PBTW + 2.5% non-fat dry milk: nNOS, 1:500; pS1412
138 phospho-nNOS, 1:250; PKG1, 1:1000; PDE5, 1:1000; sGCβ, 1:1000. Subsequently, we washed
139 membranes 5 x 5 min with PBTW, blocked with PBTW + 2.5% non-fat dry milk for 15 min, and
140 incubated with IRDye secondary antibodies (Li-Cor) at 1:7500 in PBTW + 2.5% non-fat dry milk for 50
141 min. We washed membranes 5 x 5 min with PBTW and 2 x 5 min with PBS, after which we visualized
142 proteins with an Odyssey flatbed scanner (Li-Cor). We quantified fluorescence with Li-Cor Image Studio
143 5.2 and normalized band intensity to appropriate loading controls (total nNOS protein or Ponceau total
144 protein). Housekeeping proteins (e.g., β-actin and GAPDH) are common loading controls, but recent
145 studies suggest that total protein stains (e.g., Ponceau S and Biorad Stain-Free) exhibit less variability and

146 a larger dynamic range for normalization (6, 7). In our experiments, use of GAPDH as a loading control
147 did not yield significantly different results from Ponceau S.

148

149 *Organ bath pharmacology*

150 For organ bath experiments, we used 8-26 week old virgin male mice fed a standard chow diet and
151 housed communally or in isolation. We asphyxiated mice by CO₂ and placed the ileum (the lower 40% of
152 the small bowel between the pylorus and ileocecal valve (8)) in ice-cold 95% O₂/5% CO₂ (95/5)-treated
153 Ca²⁺-free Krebs buffer. Ca²⁺-free solutions enhance ex vivo contractility of smooth muscle preparations
154 following reintroduction of Ca²⁺ (9). We removed the mesentery with scissors, discarded the 10mm of
155 ileum closest to the ileocecal valve, and flushed the ileum of solid contents with Ca²⁺-free Krebs using an
156 18-gauge blunt tip syringe. We then cut the cleaned ileal segment into 5-10mm long tissue rings and
157 applied fresh Ca²⁺-free Krebs.

158

159 We performed organ bath experiments at 37 °C in two 159920-X1/10 systems (Radnoti; Covina, CA)
160 containing eight 10ml glass chambers and two solvent reservoirs for 95/5-perfused Krebs buffer. Both
161 systems were housed in a glass-encased water jacket maintained at 37 °C and circulated by a 170051B
162 water heater-pump (ThermoFisher). We monitored ileal tension with MLT0201/RAD force transducers
163 (AD Instruments; Colorado Springs, CO), which were positioned above chambers and coupled to
164 Powerlab 16/35 (AD Instruments) with LabChart7.0 output (AD Instruments). Before mounting ilea, we
165 placed platinum electrodes (Radnoti 160152-14) in all chambers. An S88 Grass stimulator (Natus; West
166 Warwick, RI) nominally supplied 40V to each electrode via a 4-port diverter (Radnoti 159981).

167

168 To mount ileal segments, we inserted silk-threaded 10mm triangular pins (Radnoti 158817) into ileal
169 segment lumens, suspended silk strings from force transducers, placed pin-threaded ilea in Krebs-filled
170 chambers, and inserted electrode support pins into ileal segments to generate tensile force. We added
171 atropine (1μM), propranolol (1μM), phentolamine (1μM), and indomethacin (10μM) to chambers

172 containing ileal rings that exhibited spontaneous contractile activity within 15 minutes of mounting, thus
173 affording non-adrenergic, non-cholinergic (NANC) conditions (10, 11). 10 minutes after onset of NANC
174 conditions, we added substance P (1 μ M) to stimulate regular contractions (12). After cessation of tetanus
175 and with a stable baseline, we applied cumulative electric field stimulation (EFS) for 300 seconds with
176 2msec pulse width square waves of 20 V and 30 sec train duration at 0.25Hz, 0.5Hz, 1.0Hz, 2.0Hz, 4.0Hz,
177 and 8.0Hz. After the final 8.0Hz stimulation, we turned the stimulator off and recorded an additional 30
178 seconds of contractility. We did not analyze ileal segments that did not contract with substance P or that
179 did not demonstrate post-EFS contractility.

180

181 We used LabChart 7 to quantify the mean tensile force for each ileal segment. Mean tensile force is the
182 definite integral (area under the curve, or AUC) of the force function divided by the time interval. We
183 normalized mean tensile force at each EFS frequency to F_{SP} , defined as the mean baseline tension with
184 substance P (t_{max}) after tetany and before the first EFS train ($t_{0.25}$). We calculated F_{SP} as follows:

$$185 F_{SP} = (AUC_{total} - AUC_{0.25-end}) / (t_{0.25} - t_{max})$$

186 Where the AUC_{total} is AUC from t_{max} to 30 seconds after stimulation (t_{end}), calculated with respect to the
187 minimum value of the force function. (see **SI Appendix Fig. S11**).

188

189 Mean tensile forces at each EFS frequency were derived similarly:
190 $F_{0.25}$ (mean force at 0.25Hz EFS) = $(AUC_{0.25-end} - AUC_{0.5-end}) / (t_{0.5} - t_{0.25})$;
191 $F_{0.5} = (AUC_{0.5-end} - AUC_{1.0-end}) / (t_{1.0} - t_{0.5})$
192 $F_{1.0} = (AUC_{1.0-end} - AUC_{2.0-end}) / (t_{2.0} - t_{1.0})$
193 $F_{2.0} = (AUC_{2.0-end} - AUC_{4.0-end}) / (t_{4.0} - t_{2.0})$
194 $F_{4.0} = (AUC_{4.0-end} - AUC_{8.0-end}) / (t_{8.0} - t_{4.0})$
195 $F_{8.0} = (AUC_{8.0-end} - AUC_{off-end}) / (t_{off} - t_{8.0})$
196 $F_{off} = AUC_{off-end} / (t_{end} - t_{off})$

197 Where t_{off} is the time that stimulation ended. If an ileal segment's force function minimum did not
198 coincide with t_{off} , then the time at which the minimum tension did occur (t_{min}) was the upper limit of
199 integration prior to t_{min} and the lower limit of integration after t_{min} .

200

201 To measure sodium nitroprusside (SNP)-induced relaxation, we added cumulatively increasing
202 concentrations of SNP every 2 min. As before, we normalized mean tensile force at each SNP
203 concentration to the tensile force 5 min after adding substance P. To measure effects of MK-2206
204 (10 μ M), Akti-1/2 (10 μ M), H-89 (10 μ M), Myr-PKI (30 μ M), L-NAME (1mM), and TTX (10 μ M), we
205 added these compounds under NANC conditions before adding substance P, using previously published
206 concentrations sufficient to inhibit targets but low enough to avoid tissue damage and apoptosis (13-18).
207 The vehicle was 0.1% (v/v) DMSO or water as appropriate. **SI Appendix Fig. S12** contains
208 representative force-time tracings from organ bath experiments.

209

210 *nNOS purification, kinase assay, and mass spectrometry for nNOS^{S1412A} mutation*

211 We purified nNOS from nNOS^{S1412A} WT, Het., and Hom. sibling brains with 2',5'-ADP sepharose 4B and
212 assayed nNOS S1412 phosphorylation with PKA as before (5). To confirm expression of nNOS^{S1412A}, we
213 prepared partially-purified brain nNOS samples for mass spectrometry sequencing using LC-MS grade
214 solvents. We resolved samples by SDS-PAGE, stained gels with colloidal Coomassie blue, destained gel
215 pieces containing bands 125-160kDa in 200 μ L 25 mM ammonium bicarbonate in 50 % (v/v) acetonitrile
216 for 15 min, washed with 200 μ L 50% (v/v) acetonitrile, treated with 10 mM DTT at 60 °C for 30 min, and
217 alkylated with 20 mM iodoacetamide (IAA) in the dark at room temperature for 45 min. We sequentially
218 washed gel pieces with 100 μ L water and 100 μ L acetonitrile, dried via speed vac, rehydrated at 4 °C in
219 the presence of 100 ng trypsin (Millipore Sigma) for 45 min, and incubated at 37 °C overnight. Tryptic
220 mixtures were brought to 1% (v/v) formic acid + 50% acetonitrile (v/v), and peptide enriched
221 supernatants were dried via speed vac.

222

223 For LC peptide fractionation, we used an easy nanoLC 1000 liquid chromatograph (ThermoFisher) and a
224 2.7 μ m Phenomenex Cortecs C18 resin analytical column (100 μ m x 10 cm) equilibrated in 0.1% formic
225 acid. Upon sample loading, we employed a 70-min, 4-32% acetonitrile linear gradient run at 400nL/min.
226 Column eluate flowed through a nanospray ionization source of a Q Exactive quadrupole orbitrap mass

227 spectrometer (ThermoFisher). The Q Exactive was operated in positive ion mode with a target value of
228 1×10^6 ions/50msec maximum injection time, and data was acquired with Xcalibur™ 3.0 (ThermoFisher).
229 Parent peptide ions were detected at resolution 70,000 (FWHM at m/z 200) in orbitrap mode. For tandem
230 mass spectrometry, the Q Exactive subjected the 15 most abundant ions (1.2 m/z isolation window) to
231 HCD fragmentation and detected at resolution 17,500 (AGC target: 1×10^5). We used Scaffold 4.3.2
232 (Proteome Software; Portland, OR) to resolve mass chromatograms (19). Parent and fragment ion mass
233 tolerance were 2 Da and 0.1 Da, respectively, the peptide identification probability threshold (via Peptide
234 Prophet) was 95%, and one missed cleavage by trypsin was allowed. We analyzed two or more biological
235 replicates for WT and nNOS^{S1412A} samples. Total nNOS sequence coverage varied from 56-67%.

236

237 *Organ histology and immunofluorescence*

238 For histology, we fixed organs from freshly euthanized animals in Bouin's solution overnight. Paraffin-
239 embedded organs were sectioned with a microtome, mounted onto glass slides, and deparaffinized. A
240 subset of slides were used for immunofluorescence while others were stained with Masson's trichrome or
241 H&E. To quantify ileal and colonic submucosal and myenteric ganglia at 400x magnification, we
242 examined 9-12 H&E and trichrome-stained samples from 2 or more mice using a BH-2 microscope
243 (Olympus Life Science; Waltham, MA). All quantification was performed on 400x magnified images, but
244 the representative colonic micrographs in SI Appendix Fig. S5 were recorded at 200x. We obtained whole
245 mounts of ileum myenteric plexus (MP) and adjoining longitudinal smooth muscle (LM) as described
246 previously (20, 21). Briefly, we inserted a glass rod into the lumen of 5cm of terminal ileum excised after
247 euthanasia and extracted the MP and LM by rubbing forceps over the gut tube until a gap formed in the
248 LM, which permitted removing the muscle layer with a PBS-soaked cotton swab. The resulting tissue was
249 fixed in 4% (w/v) paraformaldehyde and stored in PBS at 4 °C for up to 3 months.

250

251 For immunofluorescence, we microwaved deparaffinized slides 5 min in a citrate-based buffer (Abcam).

252 After antigen retrieval, we processed slides and whole mounts identically using 0.22µm membrane-

253 filtered solutions. After washing slides or whole mounts in PBS, we permeabilized samples with 300mM
254 glycine + PBS for 30 min, rinsed with PBS 3 x 5 min, blocked with 5% (w/v) goat serum + 5% (w/v)
255 horse serum + 1% (w/v) BSA in PBT-4 for 60 min, and incubated with antibodies against nNOS (1:500)
256 and the pan-neuronal marker PGP9.5 (1:500) in PBT-2 + 1% BSA at 4 °C overnight. We then washed
257 samples with PBT-2, blocked with 2.5% goat serum + 2.5% horse serum + 1% BSA in PBT-2 for 10 min,
258 and incubated in the dark for 60 min at room temperature with Alexa Fluor 488 and 594-conjugated goat
259 antibodies against chicken and rabbit, respectively (1:1000 each in PBT-2 + 1% BSA). We rinsed samples
260 with PBT-2 4 x 5 min, followed by PBS 2 x 5 min. We visualized slides and whole mounts with an
261 Olympus CKX41 widefield fluorescence microscope and an Olympus FV1000 laser scanning confocal
262 fluorescence microscope, respectively.

263

264 *Gastrointestinal Motility Monitor (GIMM) setup and data analysis*

265 The gastrointestinal motility monitor (GIMM; Catamount Research and Development; St. Albans, VT)
266 (22-24) is a 37 °C-jacketed chamber filled with circulating 95/5-perfused Krebs buffer that enables ex
267 vivo measurement of intestinal motility. GI segments are extended to limit elastic lateral displacement to
268 ≤ 1 cm and immobilized with pins to a foam pad at the bottom of the chamber. A camera with a line of
269 sight perpendicular to the chamber records a top-down video of the GI segment's propagating and mixing
270 contraction patterns. Users define a region of interest to encompass the GI segment, and the GIMM
271 software applies a binary intensity mask to digitally distinguish the GI segment (black) from surrounding
272 buffer (white). To construct 2-dimensional spatiotemporal (ST) map jpeg files for analysis in ImageJ
273 (described below), the intensity at each pixel length is averaged across all widths for every pixel unit
274 time. For a 5cm GI segment, ST maps are 112 pixels/cm (length) x 18 pixels/sec (time). Forward time is
275 oriented downward, and the GI segment oral end faces to the left. ST maps may reveal both propagation
276 and mixing by a GI segment. *Propagation* (peristalsis) refers to unidirectional propulsion generated by
277 relaxation on one side (typically anal) and contraction on the other side (typically oral). Anterograde
278 propagating waves appear as parallel lines extending diagonally and down to the right (negative slope),

279 while retrograde propagating waves extend up to the right. *Mixing* (or segmentation) refers to
280 bidirectional, non-propulsive movement caused by similar muscle tone on both sides of a wave that
281 cyclically alternates between contraction and relaxation. Mixing waves appear as irregular sinusoids (25,
282 26). Mixing distance is sinusoidal arc length and corresponds to how fast and over how much GI segment
283 length a mixing wave occurs.

284

285 Following mouse euthanasia, we trimmed mesentery from 5cm terminal ileum segments (measured from
286 the ileocecal junction) in ice-cold Krebs buffer and placed ilea into the GIMM. We did not use NANC
287 inhibitory compounds. We traced propagation waves in ST map .jpegs to determine propagation speed
288 (defined as the slope of each line) using the GIMM ImageJ plug-in (27). We determined percentages of
289 segments that propagate by measuring the x-axis distance from beginning to end of a propagation and
290 dividing by the GI segment length (we excluded propagations that crossed the top or bottom x-axis).
291 Propagation frequency was equal to the number of propagations per unit time. We determined mixing
292 distance with ImageJ by setting the aspect ratio to zero and measuring the distance of 3-7 mixing waves
293 by freehand tracing. Mixing frequency was equal to the average number of wave crests in 3-7 mixing
294 waves per unit time. See **Fig. 5A** and **SI Appendix Fig. S13** for illustrations of GIMM setup and data
295 analysis.

296


297 *Statistical tests*

298 We performed all statistical tests with the GraphPad Prism 7.04 software (La Jolla, CA) and chose a
299 significance threshold of $p < 0.05$. For comparisons among three or more conditions, we employed one-
300 way analysis of variance (ANOVA). We conducted Dunnett or Tukey post-tests when ANOVA yielded
301 significant results. We used Dunnett tests for comparisons of experimental conditions to a control or
302 vehicle condition, and we used Tukey tests to compare all conditions or genotypes to one another. For
303 Dunnett tests, asterisks (*) refer to treatments that are significantly different from the vehicle control. For

304 Tukey tests, different letters (e.g., *a*, *b*, *c*) refer to groups that are significantly different from each other
305 (i.e., *a* is significantly different from both *b* and *c*, whereas *ab* is indistinguishable from both *a* and *b*). For
306 tensile force measurements, we performed ANOVA and post-tests at each EFS frequency. We derived
307 IC₅₀ values by non-linear logistic regression using a log [agonist] model with null hypothesis: one curve
308 explains data. For mice used in GIMM studies, we applied analysis of covariance (ANCOVA) to simple
309 linear regression models correlating weight, age, propagation speed, and mixing distance (null
310 hypotheses: identical regression line slopes and intercepts). We conducted all experiments with 3 or more
311 ileal rings obtained from 2 or more mice.

312 **Supplementary Figures**

313 **SI Appendix Fig. S1**



314


315 **Quantification of neuronal depolarization-stimulated phosphorylation of nNOS S1412 and Akt**

316 **S473 in crude lysates.** A. Low and medium frequency EFS induces nNOS S1412 phosphorylation, but

317 TTX prevents EFS-induced nNOS S1412 phosphorylation. *Left:* Representative immunoblots. *Right:*

318 Quantification of pS1412/total nNOS ratio relative to unstimulated vehicle controls. Veh: vehicle, 0.1%
319 (v/v) DMSO. Error bars: SEM. *: $p < 0.05$ vs. Veh + 0 Hz by Dunnett test. n.s.: not significant. N: number
320 of ileal rings. B. Quantification of pS473/total Akt ratio relative to unstimulated controls. N: 4-8 pooled
321 ileal rings for each lysate. C. Akt inhibitors curtail EFS-induced nNOS S1412 phosphorylation. N:
322 number of ileal rings.

323 **SI Appendix Fig. S2**



324

325 **EFS-induced ileal relaxation requires neuronal depolarization and NOS activity.** A. Inhibition of


326 NOS activity (L-NAME; 1mM) or neuronal depolarization (TTX; 10 μ M) prevents EFS-induced ileal

327 relaxation. Veh: vehicle, 0.1% (v/v) DMSO. Scale bars: 0.07g (vertical), 30sec (horizontal). B.

328 Quantification of A. Error bars: SEM. *: $p < 0.05$ vs. Veh at each frequency by Dunnett test. N: number of

329 ileal rings.

330 SI Appendix Fig. S3



331

332 **Validation of the nNOS^{S1412A} mutation.** A. Cloning strategy to produce the nNOS^{S1412A} knock-in mutant

333 mouse. The targeting construct is homologous to nNOS exon 28 and replaces the Ser1412 codon with an


334 Ala codon. B-C. Mass spectrometry of nNOS partially purified from brains of WT (B) and nNOS^{S1412A}

335 Hom. siblings (C) confirms expression of the mutant nNOS^{S1412A} protein. MS2 spectra are shown for the


336 tryptic peptide containing amino acid 1412 of nNOS (highlighted in bold). b and y ions (+1 charge state)

337 are shown in red. D. The nNOS^{S1412A} mutation blocks in vitro PKA-dependent phosphorylation of brain

338 nNOS between residues 1411 and 1425.





340 **nNOS^{S1412A} mice exhibit normal internal organ histology.** Representative formalin fixed paraffin
341 embedded (FFPE) sections stained with hematoxylin and eosin. A. Pylorus and duodenal junction. B.
342 Liver. C. Skeletal muscle. D. Heart. E. Kidney. F. Adrenal. G. Cerebellum. H. Cerebrum. I. Seminal
343 vesicle. J. Testis. Scale bar: 200µm.



345

346 **nNOS^{S1412A} mutants exhibit normal colonic histology.** A. Representative FFPE sections of colon
 347 stained with Masson's trichrome. Black arrowheads denote ganglia. Scale bar: 200µm. B. nNOS^{S1412A}
 348 mutants have normal numbers of colonic myenteric and submucosal ganglia. Error bars: SEM. MP:
 349 myenteric plexus. SMP: submucosal plexus. n.s.: not significant by one-way ANOVA. N: number of
 350 400x micrographs analyzed.



352

353 **The nNOS^{S1412A} mutation does not alter the distribution of nNOS within myenteric ganglia. A-B.**


354 Longitudinal (A) and transverse (B) cross-section illustrations of ileum. MC: mucosa. SM: submucosa.

355 SMP: submucosal plexus. CM: circular smooth muscle. MP: myenteric plexus. LM: longitudinal smooth

356 muscle. Arrowheads: SMP and MP ganglia. C. Longitudinal FFPE sections of ileum from WT and

357 nNOS^{S1412A} Het. and Hom. mice stained with antibodies against nNOS (red) and PGP9.5 (green). PGP9.5

358 and nNOS localize to MP ganglia. Scale bar: 50µm.



360


361 **EFS relaxation of ileal rings from nNOS^{S1412A} homozygotes requires NOS activity and neuronal**

362 **depolarization.** A. EFS-induced relaxation of nNOS^{S1412A} Hom. ileal rings is sensitive to the pan-NOS

363 inhibitor L-NAME (1mM) and the neuronal depolarization inhibitor TTX (10μM). Scale bars: 0.11g

364 (vertical), 30sec (horizontal). B. Quantification of A. *: p<0.05 vs. Veh by Dunnett test. n.s.: not


365 significant. N: number of ileal rings. Error bars: SEM.



367


368 **High frequency EFS relaxation of ileal rings.** A-C. EFS relaxation at high frequency for WT,
 369 nNOS^{S1412A}, and nNOS α KO ilea (A); MK-treated WT and nNOS^{S1412A} ilea (B); and eNOS KO and eNOS
 370 KO/nNOS^{S1412A} double mutant ilea (C). ¶: Data repeated from Fig. S8A for comparison. Different letters:

371 $p < 0.05$ via Tukey test at each EFS frequency. n.s.: not significant. N: number of ileal rings. Error bars:
372 SEM.




374
 375 Age and weight do not predict propagation speed or mixing distance in wildtype (●) or nNOS^{S1412A}
 376 homozygous (◆) mice. Black and blue regression lines denote WT and nNOS^{S1412A} Hom. mice,
 377 respectively. 95% confidence intervals for simple linear regressions are denoted with dotted lines. R²
 378 values denote squared Pearson correlation coefficients. We employed analysis of covariance (ANCOVA)

379 to test the null hypotheses that WT and nNOS^{S1412A} Hom. mice produce linear regressions with identical
380 slopes and intercepts. A. Age and weight are positively correlated in WT and nNOS^{S1412A} Hom. mice, but
381 the linear relationship between age and weight is not significantly different between WT and nNOS^{S1412A}
382 Hom. B-C. Propagation speed is not correlated with age or weight in WT or nNOS^{S1412A} Hom. mice. D-E.
383 Mixing distance is not correlated with age or weight in WT or nNOS^{S1412A} Hom. mice.



385
386 **Validation of NO-cGMP pathway antibodies.** A-C. Immunoblots with commercial antibodies against
387 soluble guanylate cyclase β (sGC β), cGMP-dependent protein kinase G-1 (PKG1), and
388 phosphodiesterase-5 (PDE5). GAPDH: loading control. Positive and negative controls were selected from
389 WT tissues that express high and low levels of the indicated target protein. Antibodies recognized a single
390 band of the appropriate molecular weight with expression matching previously published data and gene
391 expression databases.




$$F_{SP} = \frac{\int_{t_{max}}^{t_{0.25}} F(t)dt}{(t_{0.25} - t_{max})}$$

393


394 **Illustration of ileal contraction quantification procedure.** The blue trace represents the force tension
 395 curve of a spontaneously contracting ileal segment under NANC conditions during substance P (SP)-
 396 induced excitation and EFS-induced relaxation. AUC: area under the curve.

397



400 **Representative force-time plots for organ bath experiments.** A. Representative tracings for Fig. 1C-D.
401 Akt inhibitors (MK, Akti) suppress ileal relaxation at low EFS frequencies, but PKA inhibitors (H89,
402 PKI) do not. Scale bars: 0.1g x 30sec. B. Representative tracings for Fig 3. nNOS^{S1412A} mutant ilea are
403 less sensitive to EFS-induced relaxation than WT, but more sensitive than nNOS α KO. Akt inhibition
404 does not reduce EFS relaxation of nNOS^{S1412A}. Scale bars: 0.05g x 30sec. C. Representative tracings for
405 Fig 4A. eNOS KO ilea are as sensitive to EFS relaxation as WT, and the eNOS KO mutation does not
406 alter low frequency EFS relaxation of nNOS^{S1412A}. Double. Hom: eNOS KO nNOS^{S1412A} double mutant.
407 Scale bars: 0.04g x 30sec. D. Representative tracings for Fig 4B. Compared with WT, nNOS^{S1412A} and
408 nNOS α KO ilea are more sensitive to sodium nitroprusside (SNP)-induced relaxation. Scale bars: 0.04g x
409 30sec.
410

411 SI Appendix Fig. S13



412

413 GIMM instrument setup, data collection, and analysis. A. GIMM design. A GI segment (dark red) is

414 immobilized by two pins (white circles) in the GIMM chamber, which is filled with circulating,

415 oxygenated Krebs solution. A camera is mounted above the GI segment to record motions of the GI
416 segment. B. Data acquisition workflow using the GIMM software. The initial video (i.) is subjected to a
417 binary intensity mask (ii), and a region of interest is drawn (red box) (iii). C. Cartoon depicting the
418 correlation between motions of the GI segment in the region of interest (left) and the resulting ST map
419 (right). Black block arrows (left) denote anterograde propagating waves and are labeled with capital
420 letters with subscript numbers that refer to the time. The two anterograde propagations that occur during
421 the specified time window in the GI segment schematic are highlighted in orange in the ST map
422 schematic. Red and green block arrows denote mixing waves and are labeled with lowercase letters and
423 subscript numbers that correspond to the time. The two mixing waves that occur during the specified time
424 window in the GI segment schematic are highlighted in dark yellow in the ST map schematic. The black
425 and grey rectangles in the GI segment schematic denote small symmetry aberrations such as pieces of
426 mesentery that enable detection of mixing waves. D. Mixing contraction quantification example. 5
427 evenly-spaced mixing waves in the given ST map are chosen to estimate the average distance traversed by
428 a mixing wave in this ileal segment. The length of each mixing wave corresponds to the mixing distance.

429 SI Appendix Table S1

Genotype	WT (n=7)	nNOS ^{S1412A} Het. (n=7)	nNOS ^{S1412A} Hom. (n=7)	ANOVA p
Age (d)	179 ± 30.6	241 ± 35.7	137 ± 25.7	0.082
Whole Body (g)	35.5 ± 2.6	31.8 ± 2.3	30.9 ± 1.0	0.273
Brain (mg)	456 ± 12	419 ± 21	451 ± 6	0.17
Heart (mg)	193 ± 9	179 ± 15	161 ± 7	0.144
Adrenal (mg)	14 ± 1	14 ± 1	13 ± 1	0.891
Kidney (mg)	483 ± 18	507 ± 43	435 ± 32	0.303
Liver (mg)	1693 ± 76	1858 ± 95	1559 ± 90	0.078
Stomach (mg)	357 ± 25	413 ± 43	358 ± 18	0.346
Spleen (mg)	77 ± 4	103 ± 12	96 ± 5	0.077
Testes (mg)	356 ± 24	333 ± 26	306 ± 22	0.361
Sem. Vesicles (mg)	362 ± 33	394 ± 14	318 ± 12	0.075

430

431 Organ weights of male nNOS^{S1412A} WT, heterozygous, and homozygous siblings. Mean values and

432 SEMs are shown. Statistical significance was assessed by one-way ANOVA.

433 **SI Appendix Table S2**

Parameter	Unit	Mean Value			ANOVA p	Post-test p	
		WT (N = 7)	nNOS ^{S1412A} Het. (N = 8-9)	nNOS ^{S1412A} Hom. (N = 6-7)		WT vs Het	WT vs Hom
Propagation speed	mm* s ⁻¹	6.6 ± 0.197	7.73 ± 0.420	9.14 ± 0.710	0.0055	0.156	0.003
Percent of Ileal Segment that Propagates (Total)	%	69.1 ± 7.97	65.7 ± 6.66	67.4 ± 11.7	0.9593	0.941	0.986
Percent of Ileal Segment that Propagates Anterograde.	%	58.5 ± 11.1	35.5 ± 10.2	18.5 ± 8.59	0.0483	0.201	0.03
Percent of Ileal Segment that Propagates Retrograde.	%	11.0 ± 7.13	29.7 ± 12.1	47.9 ± 16.7	0.1497	0.445	0.098
Propagation Frequency	s ⁻¹	0.598 ± 0.030	0.576 ± 0.005	0.554 ± 0.008	0.2771	0.579	0.197
Mixing Distance	mm	46.1 ± 3.23	53.9 ± 3.36	79.9 ± 7.69	0.0004	0.433	0.0003
Mixing Frequency	s ⁻¹	0.645 ± 0.032	0.581 ± 0.005	0.575 ± 0.010	0.0394	0.051	0.047
Age	days	135.9 ± 18.8	110 ± 3.96	142.7 ± 16.1	0.2196	0.306	0.92
Weight	g	31.15 ± 2.16	30.4 ± 1.79	29.9 ± 1.64	0.9023	0.941	0.866

434

435 **GI motility monitor ANOVA and Dunnett post-test summary.** Mean values and SEMs are shown. N:

436 number of mice (and ilea) analyzed with the GIMM. Grey-colored boxes highlight significant p-values

437 (<0.05). Weight and age were not significantly different among genotypes.

438 Supplementary References

- 439 1. Shesely EG, *et al.* (1996) Elevated blood pressures in mice lacking endothelial
440 nitric oxide synthase. *Proc Natl Acad Sci U S A* 93(23):13176-13181.
- 441 2. Brenman JE, *et al.* (1996) Interaction of Nitric Oxide Synthase with the Postsynaptic Density
442 Protein PSD-95 and α 1-Syntrophin Mediated by PDZ Domains. *Cell* 84(5):757-767.
- 443 3. Huang PL, Dawson TM, Bredt DS, Snyder SH, & Fishman MC (1993) Targeted disruption of the
444 neuronal nitric oxide synthase gene. *Cell* 75(7):1273-1286.
- 445 4. Nagy A, Gertsenstein M, Vintersten K, & Behringer R (2008) Karyotyping Mouse Cells. *CSH*
446 *Protoc* 2008(5):pdb.prot4706.
- 447 5. Hurt KJ, *et al.* (2012) Cyclic AMP-dependent phosphorylation of neuronal nitric oxide synthase
448 mediates penile erection. *Proc Natl Acad Sci U S A* 109(41):16624-16629.
- 449 6. Gilda JE & Gomes AV (2013) Stain-Free total protein staining is a superior loading control to
450 beta-actin for Western blots. *Anal Biochem* 440(2):186-188.
- 451 7. Moritz CP (2017) Tubulin or Not Tubulin: Heading Toward Total Protein Staining as Loading
452 Control in Western Blots. *PROTEOMICS* 17(20):1600189.
- 453 8. Duan L-P, Wang HH, & Wang DQ-H (2004) Cholesterol absorption is mainly regulated by the
454 jejunal and ileal ATP-binding cassette sterol efflux transporters Abcg5 and Abcg8 in mice. *J*
455 *Lipid Res* 45(7):1312-1323.
- 456 9. Curro D, Volpe AR, & Preziosi P (1996) Nitric oxide synthase activity and non-adrenergic non-
457 cholinergic relaxation in the rat gastric fundus. *Br J Pharmacol* 117(4):717-723.
- 458 10. Shuttleworth CW, Sanders KM, & Keef KD (1993) Inhibition of nitric oxide synthesis reveals
459 non-cholinergic excitatory neurotransmission in the canine proximal colon. *Br J Pharmacol*
460 109(3):739-747.
- 461 11. Linden A, Ullman A, Skoogh BE, & Lofdahl CG (1992) The non-adrenergic, non-cholinergic
462 response counteracts changes in guinea-pig airway tone with and without sympathetic activation.
463 *Br J Pharmacol* 106(3):616-622.
- 464 12. Pinna C, Bolego C, & Puglisi L (1995) Effect of substance P and capsaicin on stomach fundus
465 and ileum of streptozotocin-diabetic rats. *Eur J Pharmacol* 276(1-2):61-69.
- 466 13. Denisova OV, *et al.* (2014) Akt Inhibitor MK2206 Prevents Influenza pH1N1 Virus Infection In
467 Vitro. *Antimicrob Agents Chemother* 58(7):3689-3696.
- 468 14. Leemhuis J, Boutillier S, Schmidt G, & Meyer DK (2002) The Protein Kinase A Inhibitor H89
469 Acts on Cell Morphology by Inhibiting Rho Kinase. *J Pharmacol Exp Ther* 300(3):1000-1007.
- 470 15. Kaya AI, *et al.* (2012) Cell Contact-dependent Functional Selectivity of β (2)-Adrenergic
471 Receptor Ligands in Stimulating cAMP Accumulation and Extracellular Signal-regulated Kinase
472 Phosphorylation. *J Biol Chem* 287(9):6362-6374.
- 473 16. Satin J, *et al.* (2004) Mechanism of spontaneous excitability in human embryonic stem cell
474 derived cardiomyocytes. *J Physiol* 559(Pt 2):479-496.
- 475 17. Chen X, Feng L, & Jin H (2013) Constant or fluctuating hyperglycemias increases cytomembrane
476 stiffness of human umbilical vein endothelial cells in culture: roles of cytoskeletal rearrangement
477 and nitric oxide synthesis. *BMC Cell Biol* 14(1):22.
- 478 18. Garvey EP, *et al.* (1997) 1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of
479 Inducible Nitric-oxide Synthase in Vitro and in Vivo. *J Biol Chem* 272(8):4959-4963.
- 480 19. Monks J, *et al.* (2016) Xanthine oxidoreductase mediates membrane docking of milk- fat droplets
481 but is not essential for apocrine lipid secretion. *J Physiol* 594(20):5899-5921.
- 482 20. Belkind-Gerson J, *et al.* (2017) Colitis promotes neuronal differentiation of Sox2+ and PLP1+
483 enteric cells. *Sci Rep* 7(1):2525.
- 484 21. Smith TH, Ngwainmbi J, Grider JR, Dewey WL, & Akbarali HI (2013) An In-vitro Preparation
485 of Isolated Enteric Neurons and Glia from the Myenteric Plexus of the Adult Mouse. *J Vis Exp*
486 (78):10.3791/50688.

- 487 22. Hoffman JM, Brooks EM, & Mawe GM (2010) Gastrointestinal Motility Monitor (GIMM). *J Vis*
488 *Exp* (46).
- 489 23. Wong KKL, Tang LCY, Zhou J, & Ho V (2017) Analysis of spatiotemporal pattern and
490 quantification of gastrointestinal slow waves caused by anticholinergic drugs. *Organogenesis*
491 13(2):39-62.
- 492 24. McGill M, Klinger-Lawrence M, & Herrera G (2016) Disruption of Serotonin Signaling Results
493 in Loss of Coordinated Tone Development and Subsequent Inhibition of Peristalsis in Guinea Pig
494 Distal Colon. *FASEB J* 30(1_supplement):1254.1256-1254.1256.
- 495 25. Sarna SK & Otterson MF (1988) Gastrointestinal Motility: Some Basic Concepts. *Pharmacology*
496 36(suppl 1)(Suppl. 1):7-14.
- 497 26. Janssen PW, *et al.* (2007) Characterization of flow and mixing regimes within the ileum of the
498 brushtail possum using residence time distribution analysis with simultaneous spatio-temporal
499 mapping. *J Physiol* 582(Pt 3):1239-1248.
- 500 27. Kendig DM, Hurst NR, & Grider JR (2016) Spatiotemporal Mapping of Motility in Ex Vivo
501 Preparations of the Intestines. *J Vis Exp* (107):53263.